Condensed Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Operating Expenses
Research and development	$ 53,998	$ 24,670	$ 137,162	$ 55,380
General and administrative	8,872	10,097	31,187	23,162
Total operating expenses	62,870	34,767	168,349	78,542
Operating loss	(62,870)	(34,767)	(168,349)	(78,542)
Other Income (Expense)
Investment and other income, net	99	120	313	368
Gain on deconsolidation of Zentera, net of tax	51,582	0	51,582	0
Net loss before income taxes	(11,189)	(34,647)	(116,454)	(78,174)
Income tax expense (benefit)	(697)	18	(456)	18
Net loss	(10,492)	(34,665)	(115,998)	(78,192)
Net loss attributable to noncontrolling interests	(6,301)	(110)	(7,332)	(654)
Net loss attributable to Zentalis	$ (4,191)	$ (34,555)	$ (108,666)	$ (77,538)
Net loss per common share outstanding, basic (USD per share)	$ (0.09)	$ (0.91)	$ (2.59)	$ (3.21)
Net loss per common share outstanding, diluted (USD per share)	$ (0.09)	$ (0.91)	$ (2.59)	$ (3.21)
Common shares used in computing net loss per share, basic (in shares)	44,609	37,959	41,918	24,143
Common shares used in computing net loss per share, diluted (in shares)	44,609	37,959	41,918	24,143